Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02362503 · ClinicalTrials.gov registry record · Phase 3
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
A Phase 3 study of HIV Infections, sponsored by ViiV Healthcare.
- Active
- Registry status
- Phase 3
- Development phase
- 371
- Enrollment target
- 20
- Study locations
NCT02362503 is a Phase 3 study of HIV Infections that is active but no longer recruiting, run by ViiV Healthcare. The registered enrollment target is 371 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (17% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT02362503, a Phase 3 study of HIV Infections, is active but no longer recruiting, sponsored by ViiV Healthcare.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 371 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether the BMS Attachment Inhibitor (BMS-663068) is effective in the treatment of heavily treatment experienced HIV-1 patients with multi-drug resistance.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG BMS-663068
Study Locations (20)
California
- GSK Investigational Site - Los Angeles
- GSK Investigational Site - Los Angeles
- GSK Investigational Site - Los Angeles
- GSK Investigational Site - Los Angeles
- GSK Investigational Site - Palm Springs
- GSK Investigational Site - San Francisco
Florida
- GSK Investigational Site - Ft. Pierce
- GSK Investigational Site - Orlando
- GSK Investigational Site - West Palm Beach
- GSK Investigational Site - Wilton Manors
Georgia
- GSK Investigational Site - Atlanta
- GSK Investigational Site - Atlanta
- GSK Investigational Site - Savannah
District of Columbia
- GSK Investigational Site - Washington D.C.
- GSK Investigational Site - Washington D.C.
Illinois
- GSK Investigational Site - Chicago
- GSK Investigational Site - Chicago
Colorado
- GSK Investigational Site - Denver
Connecticut
- GSK Investigational Site - New Haven
Indiana
- GSK Investigational Site - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 371 participants |
| Start Date | 2015-02-23 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02362503
The ClinicalTrials.gov registry entry for NCT02362503 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 371 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (17% lower). The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02362503 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT02362503 about?
NCT02362503 is a clinical study titled "Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients". The purpose of this study is to determine whether the BMS Attachment Inhibitor (BMS-663068) is effective in the treatment of heavily treatment experienced HIV-1 patients with multi-drug resistance.
What is the current status of trial NCT02362503?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 371 participants. The study started on 2015-02-23. Estimated completion is 2026-09-30.
What conditions does trial NCT02362503 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT02362503?
The interventions under investigation include: Placebo (OTHER), BMS-663068 (DRUG).
Who is sponsoring clinical trial NCT02362503?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02362503 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
RECRUITING · Phase 3
-
Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention
RECRUITING · Phase 3
-
SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder
RECRUITING · Phase 3
-
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
ACTIVE NOT RECRUITING · Phase 3
-
The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.